{
    "nctId": "NCT00045591",
    "briefTitle": "Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer",
    "officialTitle": "Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 39,
    "primaryOutcomeMeasure": "Progression free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n\n  * Metastatic or recurrent disease documented by physical or radiographic examination\n  * Isolated recurrence of breast cancer not considered eligible\n  * Bone disease alone allowed\n* At least 4 prior courses (or 4 months) of chemotherapy resulting in stable disease, partial response, or complete response\n* Treated brain metastases allowed provided all of the following conditions are met:\n\n  * Palliation achieved without evidence of progression for at least 3 months after completion of radiotherapy and/or surgical treatment\n  * At least 30 days since prior dexamethasone or other corticosteroids\n  * Documentation of another site of metastatic disease (in addition to brain metastases)\n* Measurable or evaluable disease\n* Pleural or peritoneal effusion as only manifestation of disease allowed if palliated by prior chemotherapy\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* CTC (ECOG) 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* AST or ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)\n* Albumin at least 3.0 g/dL\n\nRenal\n\n* Creatinine no greater than 1.5 times ULN\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No other active malignancy within the past 2 years except nonmelanoma skin cancer\n* No active peptic ulcer disease\n* No known hypersensitivity to sulfonamides, aspirin, or other NSAIDs, including celecoxib\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Concurrent trastuzumab (Herceptin) allowed if initiated at least 3 months prior to study entry\n\nChemotherapy\n\n* See Disease Characteristics\n* At least 6 weeks since prior chemotherapy\n* No more than 2 prior chemotherapy regimens for recurrent or metastatic disease\n\nEndocrine therapy\n\n* See Disease Characteristics\n* Prior hormonal therapy for metastatic disease allowed\n* No concurrent hormonal therapy except hormones for noncancer-related conditions (e.g., insulin for diabetes)\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 4 weeks since prior radiotherapy\n* Prior radiotherapy to the breast and for metastatic disease allowed\n* No concurrent palliative radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* Prior adjuvant therapy for metastatic disease allowed\n* Concurrent bisphosphonates allowed\n* Concurrent low-dose aspirin (no greater than 325 mg/day) is allowed\n* No other concurrent therapy with celecoxib or other nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib, aspirin, choline magnesium trisalicylate, ibuprofen, naproxen, etodolac, oxaprozin, diflunisal, nabumetone, or tolmetin)\n* No concurrent fluconazole",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}